BENLYSTA 400 mg/5mL
belimumab · INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · GlaxoSmithKline LLC
BENLYSTA is a injection, powder, lyophilized, for solution containing belimumab at 400 mg/5mL, taken intravenous. Manufactured by GlaxoSmithKline LLC.
Key Facts
- Brand Name
- BENLYSTA
- Generic Name
- belimumab
- NDC Code (Product)
49401-102- Manufacturer
- GlaxoSmithKline LLC
- Strength
- 400 mg/5mL
- Dosage Form
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
- Route
- INTRAVENOUS
- Marketing Status
- Application #
- BLA125370
- Drug Class
- B Lymphocyte Stimulator-specific Inhibitor [EPC]
- Marketing Start
- 03/10/2011
Recall History
No Recall HistoryFrequently Asked Questions
What is BENLYSTA used for?
BENLYSTA contains belimumab. It is a injection, powder, lyophilized, for solution taken intravenous. Consult your doctor for specific uses.
Is BENLYSTA a controlled substance?
BENLYSTA is not classified as a controlled substance by the DEA.
What is the generic name for BENLYSTA?
The generic name for BENLYSTA is belimumab. There are no other listed brand versions of belimumab.
What is the NDC code for BENLYSTA 400 mg/5mL?
The NDC (National Drug Code) for BENLYSTA 400 mg/5mL is 49401-102, listed by GlaxoSmithKline LLC.
Other BENLYSTA Dosages
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)